Beijing Hotgen Biotech Co., Ltd. (688068.SS)
CNY 116.01
(4.28%)
CNY 116.01
(4.28%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -257.13 Million CNY | 46.58% |
| 2022 | -481.36 Million CNY | 57.22% |
| 2021 | -1.12 Billion CNY | -215.93% |
| 2020 | -356.12 Million CNY | 10.77% |
| 2019 | -399.09 Million CNY | -525.85% |
| 2018 | -63.76 Million CNY | -31.64% |
| 2017 | -48.44 Million CNY | 48.08% |
| 2016 | -93.3 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -113.18 Million CNY | 49.86% |
| 2024 Q1 | -225.72 Million CNY | 12.22% |
| 2024 Q3 | -72.4 Million CNY | 42.92% |
| 2023 Q1 | -293.59 Million CNY | 39.01% |
| 2023 Q2 | -303.18 Million CNY | -3.27% |
| 2023 Q4 | -257.13 Million CNY | -47.07% |
| 2023 Q3 | -174.83 Million CNY | 42.33% |
| 2023 FY | -257.13 Million CNY | 46.58% |
| 2022 Q4 | -481.36 Million CNY | 19.76% |
| 2022 Q3 | -599.88 Million CNY | 6.38% |
| 2022 Q1 | -615.95 Million CNY | 45.25% |
| 2022 Q2 | -640.78 Million CNY | -4.03% |
| 2022 FY | -481.36 Million CNY | 57.22% |
| 2021 Q2 | -460.29 Million CNY | 42.48% |
| 2021 Q1 | -800.25 Million CNY | -123.68% |
| 2021 FY | -1.12 Billion CNY | -215.93% |
| 2021 Q3 | -296.3 Million CNY | 35.63% |
| 2021 Q4 | -1.12 Billion CNY | -279.7% |
| 2020 FY | -356.12 Million CNY | 10.77% |
| 2020 Q2 | -56.79 Million CNY | -93.92% |
| 2020 Q3 | -40.96 Million CNY | 27.87% |
| 2020 Q4 | -357.76 Million CNY | -773.24% |
| 2020 Q1 | -29.29 Million CNY | 92.66% |
| 2019 Q1 | 63.76 Million CNY | 200.0% |
| 2019 FY | -399.09 Million CNY | -525.85% |
| 2019 Q4 | -399.09 Million CNY | 3.38% |
| 2019 Q3 | -413.05 Million CNY | -2115.5% |
| 2019 Q2 | -18.64 Million CNY | -129.24% |
| 2018 Q4 | -63.76 Million CNY | 0.0% |
| 2018 FY | -63.76 Million CNY | -31.64% |
| 2017 FY | -48.44 Million CNY | 48.08% |
| 2016 FY | -93.3 Million CNY | 0.0% |